Velilla G, Carrión C J, Portillo J A, Truán D, Azueta A, Fuentes J, Herrero E, Gala L
Servicio de Urología, Hospital Universitario Marqués de Valdecilla, Santander, España.
Servicio de Urología, Hospital Universitario Marqués de Valdecilla, Santander, España.
Actas Urol Esp. 2016 Apr;40(3):195-200. doi: 10.1016/j.acuro.2015.11.008. Epub 2015 Dec 31.
Microcytic carcinoma of the urinary bladder or bladder Small Cell Carcinoma (SCC) is a rare entity, characterised by an aggressive behaviour, with a poor prognosis, elevated metastatic potential, and is commonly found in older patients and in advanced disease stages. Here we present our experiences with the behaviour of the disease and the treatments applied.
This was a retrospective study on patients diagnosed with bladder SCC in our hospital between February 1992 and February 2014. We analysed the demographic and clinical characteristics of the tumour, the applied treatments and survival. We performed a descriptive statistical analysis of the median follow-up time, Overall Survival (OS) and Cancer-Specific Survival (CSS), using the SPSS statistical package v. 15.0.
Over 22 years, 20 patients with an average age of 75 years were diagnosed with bladder SCC (2 female). The predominant symptom was macroscopic haematuria (75%). After the first transurethral resection (TUR) of the bladder and the histological diagnosis, 35% (7 patients) did not receive additional treatment, 15% (3 patients) were treated with chemoradiotherapy (CRT), 10% (2 patients) with TUR, 15% (3 patients) with chemotherapy (QT), 5% (1 patient) with TUR associated to CRT, 5% (1 patient) with radical surgery, 5% (1 patient) with radical surgery treatment followed by adjuvant CRT, 5% (1 patient) with palliative surgery (hypogastric arteriae ligation) followed by adjuvant QT and 5% (1 patient) with hemostatic radiotherapy (RT). With a median follow-up time of 13.8 months, the OS was 14.48 months (95% CI: 6.22 - 22.75) and the CSS 18.04 months (95% CI: 6.51-29.57). Only 10% (2 patients) survived till the end of the study.
Microcytic carcinoma of the urinary bladder is a rare and aggressive entity commonly diagnosed in males of advanced age and in advanced disease stages. It has a poor prognosis and reduced survival. Due to its aggressiveness previous to the initial diagnosis, a cystectomy is only possible in very few cases; therefore multimodal treatment is necessary. This treatment is yet to be defined.
膀胱微细胞癌或膀胱小细胞癌（SCC）是一种罕见的疾病，其特点是具有侵袭性，预后较差，转移潜力高，常见于老年患者且处于疾病晚期。在此，我们介绍我们在该疾病行为及所应用治疗方法方面的经验。
这是一项对1992年2月至2014年2月期间在我院被诊断为膀胱SCC的患者进行的回顾性研究。我们分析了肿瘤的人口统计学和临床特征、所应用的治疗方法及生存率。我们使用SPSS统计软件包v. 15.0对中位随访时间、总生存期（OS）和癌症特异性生存期（CSS）进行了描述性统计分析。
在22年期间，20例平均年龄为75岁的患者被诊断为膀胱SCC（2例女性）。主要症状为肉眼血尿（75%）。在首次经尿道膀胱肿瘤切除术（TUR）及组织学诊断后，35%（7例患者）未接受额外治疗，15%（3例患者）接受了放化疗（CRT），10%（2例患者）接受了TUR，15%（3例患者）接受了化疗（QT），5%（1例患者）接受了与CRT相关的TUR，5%（1例患者）接受了根治性手术，5%（1例患者）接受了根治性手术治疗后辅助CRT，5%（1例患者）接受了姑息性手术（腹下动脉结扎）后辅助QT，5%（1例患者）接受了止血放疗（RT）。中位随访时间为13.8个月，OS为14.48个月（95%置信区间：6.22 - 22.75），CSS为18.04个月（95%置信区间：6.51 - 29.57）。只有10%（2例患者）存活至研究结束。
膀胱微细胞癌是一种罕见且具有侵袭性的疾病，常见于老年男性且处于疾病晚期。其预后较差，生存率降低。由于其在初始诊断前具有侵袭性，只有极少数情况下可行膀胱切除术；因此，多模式治疗是必要的。这种治疗方法尚待确定。
